Genmab — Maj 2018
-
Jefferies:
The news dents sentiment given the blockbuster potential
optionality, with headline readouts previously eagerly awaited
in 2H -
BofA Merrill Lynch sænker til Neutral fra Køb/Overvægt
-
BofA Merrill Lynch: Darzalex solid tumour data was the key catalyst for FY18 and that there is limited other material positive share price catalysts in the next 12 mths.
-
Som sagt bringer det hele denne gamle sag i erindring: Merck announced that it was postponing enrollment in KEYNOTE-183 and KEYNOTE-185 after an independent data monitoring committee noted an imbalance in deaths among patients with multiple myeloma assigned to combination therapy involving pembrolizumab and immunomodulatory treatment.
-
Selv om jeg er helt enig i, at Genmab ikke er ansvarlig for markedets reaktioner på pressemeddelelsen så er problemet vel alligevel lidt det, at et problem for PD1 opfattes som et problem for Dara (se blot Bowers mærkelige udlægning). . Det kunne man godt have undgået med en lidt anden ordlyd
-
Jeg ved ikke rigtig i hvilket omfang Jan har hypet Dara i fste tumorer. Syntes mere at hans primære fokus har været andet steds:https://medwatch.dk/secure/Medicinal___Biotek/article10024820.ece
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind